US Patent Issued to ASCENDIS PHARMA GROWTH DISORDERS on Feb. 10 for "Controlled-release CNP agonists with reduced side-effects" (German, Danish Inventors)

ALEXANDRIA, Va., Feb. 11 -- United States Patent no. 12,544,428, issued on Feb. 10, was assigned to ASCENDIS PHARMA GROWTH DISORDERS A/S (Hellerup, Denmark).

"Controlled-release CNP agonists with reduced side-effects" was invented by Kennett Sprogoe (Holte, Denmark), Harald Rau (Dossenheim, Germany), Felix Cleemann (Mainz, Germany) and Ulrich Hersel (Heidelberg, Germany).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates a pharmaceutical composition comprising a controlled-release CNP agonist which reduces CNP agonist-associated side-effects, the use of such controlled-release CNP agonist and to methods of treatment."

The patent was filed on May 24, 2022, under Application No. 17/75...